Misonix Showcases SonicOne Ultrasonic Wound Debrider with Medline at MEDICA 2006, the Leading International Medical Trade Fair, in Germany

FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced its participation in MEDICA 2006, the world's leading international medical trade fair, to be held November 15-18, 2006, at the Düsseldorf Trade Fair Centre in Germany. The participation of Misonix is intended to support its recently commercialized Ultrasonic Wound Debridement System marketed as SonicOne® in the United States.

“By participating in MEDICA 2006, Misonix will be on a global stage to promote the latest in medical device technology in the SonicOne, which makes a substantial improvement for patients and healthcare practitioners in the advanced wound care market”

Misonix and Medline Industries, its U.S. distribution partner for SonicOne, will be meeting with potential customers and other constituents from the healthcare industry. Misonix internally developed the SonicOne and manufactures the product at its global headquarters in Farmingdale, Long Island, New York. As a technologically advanced ultrasonic medical device for wound care, Misonix’s intellectual property for the SonicOne is protected by patents which have already been issued as well as patents which are pending. The SonicOne allows healthcare practitioners to remove necrotic tissue, biofilm, and other impediments to successful wound healing.

“By participating in MEDICA 2006, Misonix will be on a global stage to promote the latest in medical device technology in the SonicOne, which makes a substantial improvement for patients and healthcare practitioners in the advanced wound care market,” said Michael A. McManus Jr., President and Chief Executive Officer of Misonix. “Furthermore, with the SonicOne powered by Misonix’s proprietary ultrasound technology, the conference provides us with an ideal setting to broaden awareness of our Company in global markets with the objective of expanding distribution and creating partnerships for our platform of world class ultrasonic medical devices available today and other important devices in our development pipeline.”

About Misonix:

Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix’s ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.